Trials / Unknown
UnknownNCT02081339
Cohort Study of the Clinical Course of Macular Diseases in Japanese
Cohort Study of the Clinical Course of Macular Diseases in Japanese Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Kyoto University, Graduate School of Medicine · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. Patients with such macular diseases are registered and and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ranibizumab, aflibercept, pegaptanib, verteporphin |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2022-03-01
- Completion
- 2024-03-01
- First posted
- 2014-03-07
- Last updated
- 2016-09-23
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02081339. Inclusion in this directory is not an endorsement.